[Federal Register: September 30, 2004 (Volume 69, Number 189)]
[Notices]
[Page 58542]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr30se04-128]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated May 18, 2004, and published in the Federal Register
on June 3, 2004, (69 FR 31412-31413), Abbott Laboratories, DBA Knoll
Pharmaceutical Company, 30 North Jefferson Road, Whippany, New Jersey
07981, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the
basic classes of controlled substances listed:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Dihydromorphine (9145)..................... I
Hydromorphone (9150)....................... II
------------------------------------------------------------------------
The company plans to manufacture bulk product and finished dosage
units for distribution to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Abbott Laboratories to manufacture the listed basic classes of
controlled substances is consistent with the public interest at this
time. DEA has investigated Abbott Laboratories to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with
21 CFR 1301.33, the above named company is granted registration as a
bulk manufacturer of the basic classes of controlled substances listed.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 04-21952 Filed 9-29-04; 8:45 am]
BILLING CODE 4410-09-M